Information for HCPs | Enbrel® (etanercept)

1 2 3

An inside look at patient and professional perspectives on treating psoriatic arthritis
and moderately to severely active rheumatoid arthritis (RA).

Approach It Like A Pro

Watch the Documentary

Phil Mickelson, Champion golfer and ENBREL PsA patient

ENBREL helps improve clinical symptoms and physical function, and helps stop joint damage

See Phil's Story See efficacy in psoriatic arthritis

*Initial clinical research in RA patients began in 1993. Approved to treat moderate to severe RA in 1998.¹

1. Data on file, Amgen and Pfizer, Inc.

View the experience of ENBREL

Important Safety Considerations

The ENBREL Support™ card offers eligible patients*:

First 6 months $0 out-of-pocket costs per month

After 6 months $10 or less out-of-pocket costs per month†

Learn more about financial assistance

ENBREL Support™ Card Criteria:

*Eligibility ^†Limits

Open to patients with commercial prescription insurance. Not open to uninsured patients or patients receiving prescription reimbursement under any state, federal, or government-funded insurance programs (for example, Medicare including Medicare Part D, Medicaid, etc.) or where prohibited by law. Restrictions may apply. Offer subject to change or discontinuation without notice. This is not health insurance.

Program provides up to $4,000 of assistance per patient for each 6-month period. Patient is responsible for costs above these amounts.

Prescribing Information Medication Guide

INDICATIONS

ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.

ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

Supportive data

Moderate to Severe Rheumatoid Arthritis

In medical studies, ENBREL was shown to be clinically effective in about 2 out of 3 adults with moderate to severe RA at 3 months. ENBREL has been shown to begin working in as few as 2 weeks, and most patients who benefit will do so within 3 months. In another medical study, 55% of patients who were evaluated 5 years after beginning ENBREL therapy had no further progression of joint damage.

Psoriatic Arthritis

In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.

You are leaving Enbrel.com/RheumPro

Please know that Amgen and Pfizer do not endorse and are not responsible for the content included on the site you are about to enter. Click the "Continue" button to proceed.

Continue Cancel

To return to ENBREL.com, click "Cancel" or close this window.

Privacy Policy Terms of Use
This site is intended for US Audiences only.
©2013 Amgen, Inc., Thousand Oaks, CA 91320 and Pfizer Inc

E-mail this page to a colleague

Please correct the fields marked in red

Your E-mail

Colleague's E-mail

Send

This content is for US health care professionals only. Amgen and Pfizer will not use your e-mail address or your colleague's e-mail address for any other purpose. To learn more about our use of your information and your rights, please consult our Privacy Policy.

Your e-mail was sent successfully.

Send another e-mail
Return to enbrel.com/RheumPro

Notice

The following information is intended for use only by residents of the United States. Countries outside of the United States may have regulatory requirements or medical practices that are different than those in the United States and may require reference to different or additional information. Therefore, this information may not be appropriate outside of the United States.

If you are a resident of the United States or one of its territories, or a health care professional practicing your profession in the United States or one of its territories, please click below.

Continue

If you are a resident of a country other than the United States, please visit the Pfizer website and the Amgen website to find information about our offices around the globe.

Phil Mickelson: A patient's perspective

Disease activity vs. structural progression in RA